Replies to post #245615 on Biotech Values

[DewDiligence]

JNCE—(+24%/AH)—receives $1.80/sh +CVR counteroffer_from Tang Capital:

https://www.sec.gov/Archives/edgar/data/1640455/000121465923003818/o314231sc13d.htm (scan to bottom)

The proposed CVR for JNCE shareholders is identical to the CVR in the previously announced REDX deal (#msg-171282176).